News

Business Outlook

Is the Internet of Things Our Biggest Future Threat?

IRIS.xyz | Equities.com |

According to a recent report, only 28 percent of those organizations consider their IoT security strategy to be “very important,”


​3 EURONEXT 100 IDX Firms that can Offer an Insight into the Investment Market

Zak Goldberg | Equities.com |

A look into three EURONEXT 100 firms.


Integration Should Be Priority No. 1 for Acquisition-Minded Fintechs

Josh Dennis | Equities.com |

Companies with suite-based solutions are receiving a lot of attention from investors lately. However, a suite is an asset only when the constituent parts cooperate.


Can You Really Sue Fortnite for 'Stealing' Your Dance Moves?

Guardian Web | Equities.com |

The answer is yes. Kind of. It’s complicated.


FedEx Warns of Global Slowdown: Expect More Warnings

Mish Shedlock | Equities.com |

FedEx still insists the economy is solid, but it slashed its forecast due to a Global Trade Slowdown.


Jeremy Grantham: Investing Was So Much Easier 40 Years Ago

The Acquirer’s Multiple® | Equities.com |

What's changed?


Turn Fearful Clients Into Fearless Investors

IRIS.xyz | Equities.com |

Here's how this tool could be the differentiator between you and the advisor down the street.


Is a Strong US Dollar Beneficial for the Global Financial Market?

Faizan Raza | Equities.com |

As a result, Is a Strong US Dollar Beneficial for the Global Financial Market?


What’s Wrong With the Millennial Money Mindset?

Andrew Deen | Equities.com |

The millennial generation is marked by drive and passion, plus a well-rounded focus that involves more than making money. Yet, they’re not financially illiterate, nor are they excessively impulsive.


​Bringing Back a Poorly Performing Startup

Gary C. Bizzo | Equities.com |

Not all startups are created equal and most, often than not, fail rather than have outstanding success.


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more